INSM vs. PTCT, CCXI, TGTX, FTSV, SDGR, VTRS, UTHR, SRPT, RDY, and CTLT
Should you be buying Insmed stock or one of its competitors? The main competitors of Insmed include PTC Therapeutics (PTCT), ChemoCentryx (CCXI), TG Therapeutics (TGTX), Forty Seven (FTSV), Schrödinger (SDGR), Viatris (VTRS), United Therapeutics (UTHR), Sarepta Therapeutics (SRPT), Dr. Reddy's Laboratories (RDY), and Catalent (CTLT). These companies are all part of the "medical" sector.
Insmed (NASDAQ:INSM) and PTC Therapeutics (NASDAQ:PTCT) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.
Insmed has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500.
PTC Therapeutics received 34 more outperform votes than Insmed when rated by MarketBeat users. However, 64.83% of users gave Insmed an outperform vote while only 61.83% of users gave PTC Therapeutics an outperform vote.
In the previous week, Insmed had 2 more articles in the media than PTC Therapeutics. MarketBeat recorded 27 mentions for Insmed and 25 mentions for PTC Therapeutics. Insmed's average media sentiment score of 0.70 beat PTC Therapeutics' score of 0.47 indicating that Insmed is being referred to more favorably in the media.
Insmed currently has a consensus target price of $44.93, suggesting a potential downside of 6.52%. PTC Therapeutics has a consensus target price of $35.67, suggesting a potential downside of 2.20%. Given PTC Therapeutics' higher probable upside, analysts plainly believe PTC Therapeutics is more favorable than Insmed.
PTC Therapeutics has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.
PTC Therapeutics has a net margin of -62.45% compared to Insmed's net margin of -236.74%.
Summary
Insmed beats PTC Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Insmed News Delivered to You Automatically
Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
